Monopar Therapeutics Publishes Phase 2 Results for ALXN1840 in Wilson Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Monopar Therapeutics announced that the Phase 2 open-label trial of ALXN1840 in patients with Wilson disease demonstrated a significant average reduction of 6.08 mg in copper balance after 21 days of daily dosing, indicating the drug's efficacy in copper metabolism regulation.
- Innovative Drug Mechanism: ALXN1840, as the first Albumin Tripartite Complex (ATC) activator, mobilizes and sequesters copper, suppressing its redox reactivity and limiting its transport across the blood-brain barrier, showcasing a unique therapeutic mechanism.
- Good Tolerability: The trial indicated that ALXN1840 was generally well-tolerated with no serious adverse events reported, highlighting its safety in clinical applications and laying a foundation for future market promotion.
- Optimistic Market Outlook: With ALXN1840 showing significant copper mobilization effects in a completed 48-week Phase 3 trial involving 266 patients, the drug is poised to become a new standard in Wilson disease treatment, further enhancing Monopar's competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNPR
Wall Street analysts forecast MNPR stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.430
Low
95.00
Averages
112.91
High
130.00
Current: 64.430
Low
95.00
Averages
112.91
High
130.00
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Monopar Therapeutics Publishes Phase 2 Results for ALXN1840 in Wilson Disease
- Clinical Trial Results: Monopar Therapeutics announced that the Phase 2 open-label trial of ALXN1840 in patients with Wilson disease demonstrated a significant average reduction of 6.08 mg in copper balance after 21 days of daily dosing, indicating the drug's efficacy in copper metabolism regulation.
- Innovative Drug Mechanism: ALXN1840, as the first Albumin Tripartite Complex (ATC) activator, mobilizes and sequesters copper, suppressing its redox reactivity and limiting its transport across the blood-brain barrier, showcasing a unique therapeutic mechanism.
- Good Tolerability: The trial indicated that ALXN1840 was generally well-tolerated with no serious adverse events reported, highlighting its safety in clinical applications and laying a foundation for future market promotion.
- Optimistic Market Outlook: With ALXN1840 showing significant copper mobilization effects in a completed 48-week Phase 3 trial involving 266 patients, the drug is poised to become a new standard in Wilson disease treatment, further enhancing Monopar's competitive position in the market.
See More
Monopar Plans to File New Drug Application for Wilson Disease Treatment
- New Drug Application Plans: Monopar plans to file a New Drug Application for ALXN1840 in mid-2026 to treat Wilson disease, a rare genetic disorder causing dangerous copper accumulation in organs, indicating the company's strategic focus on rare diseases.
- Clinical Trial Results: In a mid-stage clinical study, ALXN1840 significantly improved copper balance in Wilson disease patients by enhancing copper excretion through stool, delivering rapid and sustained benefits even after an average of 16 years on standard treatments, showcasing the drug's potential.
- Strong Financial Position: Monopar noted it has sufficient cash to fund operations through at least the end of 2027, providing financial stability for new drug development and market readiness, which boosts investor confidence.
- Positive Market Reaction: Retail sentiment around MNPR stock shifted from 'neutral' to 'bullish' in the past 24 hours, with high message volume, reflecting optimistic expectations for ALXN1840, as the stock has risen about 50% over the past year.
See More
Monopar Announces Significant Progress in Wilson Disease Treatment
- Clinical Trial Results: Monopar Therapeutics' published study indicates that ALXN1840 (tiomolibdate choline) achieved a statistically significant improvement in daily copper balance in Wilson disease patients, with a mean decrease of 6.08 mg over 21 days, highlighting the drug's potential in treatment.
- Study Design and Implementation: The open-label Phase 2 trial was conducted across two centers in the UK and New Zealand, involving nine patients who were placed on a copper-controlled diet while receiving ALXN1840, resulting in a significant 50% increase in daily fecal copper excretion.
- Safety and Tolerability: Throughout the trial, ALXN1840 was generally well tolerated with no serious adverse events reported, indicating its safety for long-term use and laying a foundation for future market introduction.
- Market Outlook: The findings underscore ALXN1840's significance in treating Wilson disease, potentially offering new therapeutic options for patients, especially where existing treatments have limited efficacy, thus presenting substantial market potential.
See More
Monopar Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Monopar Therapeutics reported a Q1 GAAP EPS of -$0.46, beating expectations by $0.36, indicating improved financial management that could bolster investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Monopar holds $137.5 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for at least the next two years to support its R&D and commercial activities.
- Clear Funding Utilization Plan: The company expects its current funds to sustain operations through December 31, 2027, covering regulatory and potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal R&D, reflecting a well-defined strategic plan.
- Ongoing R&D Commitment: Monopar will continue to advance the development of the MNPR-101 program, demonstrating its strong commitment to innovative drug development, which may establish a competitive edge in the market.
See More
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Financial Overview: As of March 31, 2026, Monopar's cash and cash equivalents stood at $137.5 million, which is expected to support operations through December 31, 2027, ensuring funding for future R&D and commercial activities.
- R&D Expense Increase: R&D expenses for Q1 2026 reached $3.487 million, a 112.5% increase from $1.643 million in Q1 2025, primarily due to significant rises in contractor and personnel costs, reflecting the company's ongoing commitment to drug development.
- Net Loss Situation: The net loss for Q1 2026 was $3.9 million, or $0.46 per share, compared to a net loss of $2.6 million and $0.38 per share in Q1 2025, indicating higher costs associated with expanding R&D and market readiness efforts.
- Interest Income Growth: Interest income for Q1 2026 was $1.332 million, up 123% from $596,845 in Q1 2025, primarily driven by increased earnings from U.S. Treasury securities and commercial paper, showcasing effective financial management by the company.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Monopar Therapeutics Publishes Phase 2 Results for ALXN1840 in Wilson Disease
- Clinical Trial Results: Monopar Therapeutics announced that the Phase 2 open-label trial of ALXN1840 in patients with Wilson disease demonstrated a significant average reduction of 6.08 mg in copper balance after 21 days of daily dosing, indicating the drug's efficacy in copper metabolism regulation.
- Innovative Drug Mechanism: ALXN1840, as the first Albumin Tripartite Complex (ATC) activator, mobilizes and sequesters copper, suppressing its redox reactivity and limiting its transport across the blood-brain barrier, showcasing a unique therapeutic mechanism.
- Good Tolerability: The trial indicated that ALXN1840 was generally well-tolerated with no serious adverse events reported, highlighting its safety in clinical applications and laying a foundation for future market promotion.
- Optimistic Market Outlook: With ALXN1840 showing significant copper mobilization effects in a completed 48-week Phase 3 trial involving 266 patients, the drug is poised to become a new standard in Wilson disease treatment, further enhancing Monopar's competitive position in the market.
See More
Monopar Plans to File New Drug Application for Wilson Disease Treatment
- New Drug Application Plans: Monopar plans to file a New Drug Application for ALXN1840 in mid-2026 to treat Wilson disease, a rare genetic disorder causing dangerous copper accumulation in organs, indicating the company's strategic focus on rare diseases.
- Clinical Trial Results: In a mid-stage clinical study, ALXN1840 significantly improved copper balance in Wilson disease patients by enhancing copper excretion through stool, delivering rapid and sustained benefits even after an average of 16 years on standard treatments, showcasing the drug's potential.
- Strong Financial Position: Monopar noted it has sufficient cash to fund operations through at least the end of 2027, providing financial stability for new drug development and market readiness, which boosts investor confidence.
- Positive Market Reaction: Retail sentiment around MNPR stock shifted from 'neutral' to 'bullish' in the past 24 hours, with high message volume, reflecting optimistic expectations for ALXN1840, as the stock has risen about 50% over the past year.
See More
Monopar Announces Significant Progress in Wilson Disease Treatment
- Clinical Trial Results: Monopar Therapeutics' published study indicates that ALXN1840 (tiomolibdate choline) achieved a statistically significant improvement in daily copper balance in Wilson disease patients, with a mean decrease of 6.08 mg over 21 days, highlighting the drug's potential in treatment.
- Study Design and Implementation: The open-label Phase 2 trial was conducted across two centers in the UK and New Zealand, involving nine patients who were placed on a copper-controlled diet while receiving ALXN1840, resulting in a significant 50% increase in daily fecal copper excretion.
- Safety and Tolerability: Throughout the trial, ALXN1840 was generally well tolerated with no serious adverse events reported, indicating its safety for long-term use and laying a foundation for future market introduction.
- Market Outlook: The findings underscore ALXN1840's significance in treating Wilson disease, potentially offering new therapeutic options for patients, especially where existing treatments have limited efficacy, thus presenting substantial market potential.
See More
Monopar Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Monopar Therapeutics reported a Q1 GAAP EPS of -$0.46, beating expectations by $0.36, indicating improved financial management that could bolster investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Monopar holds $137.5 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for at least the next two years to support its R&D and commercial activities.
- Clear Funding Utilization Plan: The company expects its current funds to sustain operations through December 31, 2027, covering regulatory and potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal R&D, reflecting a well-defined strategic plan.
- Ongoing R&D Commitment: Monopar will continue to advance the development of the MNPR-101 program, demonstrating its strong commitment to innovative drug development, which may establish a competitive edge in the market.
See More
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Financial Overview: As of March 31, 2026, Monopar's cash and cash equivalents stood at $137.5 million, which is expected to support operations through December 31, 2027, ensuring funding for future R&D and commercial activities.
- R&D Expense Increase: R&D expenses for Q1 2026 reached $3.487 million, a 112.5% increase from $1.643 million in Q1 2025, primarily due to significant rises in contractor and personnel costs, reflecting the company's ongoing commitment to drug development.
- Net Loss Situation: The net loss for Q1 2026 was $3.9 million, or $0.46 per share, compared to a net loss of $2.6 million and $0.38 per share in Q1 2025, indicating higher costs associated with expanding R&D and market readiness efforts.
- Interest Income Growth: Interest income for Q1 2026 was $1.332 million, up 123% from $596,845 in Q1 2025, primarily driven by increased earnings from U.S. Treasury securities and commercial paper, showcasing effective financial management by the company.
See More
